摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-Methyl-7-(3-nitro-phenyl)-1,2,3,7-tetrahydro-indolizine-6,8-dicarboxylic acid 8-ethyl ester 6-methyl ester | 50620-92-3

中文名称
——
中文别名
——
英文名称
5-Methyl-7-(3-nitro-phenyl)-1,2,3,7-tetrahydro-indolizine-6,8-dicarboxylic acid 8-ethyl ester 6-methyl ester
英文别名
5-Methyl-7-(3-nitrophenyl)-1,2,3,7-tetrahydroindolizine-6,8-dicarboxylic acid 6-methyl ester 8-ethyl ester;8-O-ethyl 6-O-methyl 5-methyl-7-(3-nitrophenyl)-1,2,3,7-tetrahydroindolizine-6,8-dicarboxylate
5-Methyl-7-(3-nitro-phenyl)-1,2,3,7-tetrahydro-indolizine-6,8-dicarboxylic acid 8-ethyl ester 6-methyl ester化学式
CAS
50620-92-3
化学式
C20H22N2O6
mdl
——
分子量
386.404
InChiKey
WIWBBRAOOQCHED-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    28
  • 可旋转键数:
    6
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    102
  • 氢给体数:
    0
  • 氢受体数:
    7

反应信息

  • 作为产物:
    描述:
    3-Nitrobenzylideneacetoacetic acid methyl ester 、 ethyl pyrrolidinylidene acetate乙醇溶剂黄146 反应 8.0h, 以5-methyl-7-(3-nitrophenyl)-1,2,3,7-tetrahydroindolizine-6,8-dicarboxylic acid 6-methyl ester 8-ethyl ester of melting point 120° (ethanol) is obtained的产率得到5-Methyl-7-(3-nitro-phenyl)-1,2,3,7-tetrahydro-indolizine-6,8-dicarboxylic acid 8-ethyl ester 6-methyl ester
    参考文献:
    名称:
    Compositions and methods employing tetrahydroindolizine derivatives
    摘要:
    在3-和5-位置带有羰基功能的1,4-二氢吡啶,可以在6-位置被低级烷基取代,4-位置被低级烷基、苯基、取代苯基或杂环基取代,并通过1-和2-位置与五、六或七元环烷基环融合,其中一种亚甲基基团可以被硫、氧、亚胺或烷基亚胺取代,是抗高血压药物和冠状血管扩张剂。这些化合物,其中6-甲基-4-(3-硝基苯基)-1,2-戊亚甲基-1,4-二氢吡啶-3,5-二羧酸3,5-二乙酯是一个具有代表性的实施例,可以通过酰乙酰乙酸酯和环状烯胺羰基衍生物的缩合制备。
    公开号:
    US04024261A1
点击查看最新优质反应信息

文献信息

  • 1,2-Pentamethylene-1,4-dihydropyridine derivatives
    申请人:Bayer Aktiengesellschaft
    公开号:US03951988A1
    公开(公告)日:1976-04-20
    1,4-Dihydropyridines bearing carbonyl functions in the 3- and 5-positions, being optionally substituted by lower alkyl in the 6-position, being substituted in the 4-position by lower alkyl, phenyl, substituted phenyl or a heterocyclic group, and being fused through the 1- and 2-positions to a five, six or seven membered cycloalkyl ring, one methylene group of which can be replaced by sulfur, oxygen imino or alkylimino, are antihypertensive agents and coronary vessel dilators. The compounds, of which 6-methyl-4-(3-nitrophenyl)-1,2-pentamethylene-1,4-dihydropyridine-3,5-dica rboxylic acid 3,5-diethyl ester is a representative embodiment, are prepared through condensation of an ylideneacetoacetic acid ester and a cyclic enamino carbonyl derivative.
    3-和5-位带有羰基功能的1,4-二氢吡啶,可在6位被低烷基取代,在4位被低烷基、苯基、取代苯基或杂环基取代,并通过1-和2-位与五、六或七元环烷基环融合,其中一个亚甲基可以被、氧、亚胺或烷基亚胺取代,是降压剂和冠状血管扩张剂。这些化合物,其中6-甲基-4-(3-硝基苯基)-1,2-戊亚甲基-1,4-二氢吡啶-3,5-二羧酸3,5-二乙酯是一个典型实施例,是通过酰乙酸酯和环烯酮羰基衍生物的缩合反应制备的。
  • Tetrahydroimidazolo[1,2-a]pyridine derivatives
    申请人:Bayer Aktiengesellschaft
    公开号:US03935220A1
    公开(公告)日:1976-01-27
    1,4-Dihydropyridines bearing carbonyl functions in the 3- and 5-positions, being optionally substituted by lower alkyl in the 6-position, being substituted in the 4-position by lower alkyl, phenyl, substituted phenyl or a heterocyclic group, and being fused through the 1- and 2-positions to a five, six or seven membered cycloalkyl ring, one methylene group of which can be replaced by sulfur, oxygen imino or alkylimino, are antihypertensive agents and coronary vessel dilators. The compounds, of which 6-methyl-4-(3-nitrophenyl)-1,2-pentamethylene-1,4-dihydropyridine-3,5-dica rboxylic acid 3,5-diethyl ester is a representative embodiment, are prepared through condensation of an ylideneacetoacetic acid ester and a cyclic enamino carbonyl derivative.
    3-和5-位带有羰基功能的1,4-二氢吡啶,6-位可选择性地被低碳基取代,4-位被低碳基、苯基、取代苯基或杂环基所取代,并通过1-和2-位融合到五、六或七元环烷基环上,其中一个亚甲基可以被、氧、亚基或烷基亚基所取代,是抗高血压药和冠状血管扩张剂。这些化合物,其中6-甲基-4-(3-硝基苯基)-1,2-戊亚甲基-1,4-二氢吡啶-3,5-二羧酸3,5-二乙酯是一个代表性实施例,是通过酰乙酰酸酯和环状烯酮羰基衍生物的缩合制备的。
  • Pentahydroqunolizine derivatives
    申请人:Bayer Aktiengesellschaft
    公开号:US03948923A1
    公开(公告)日:1976-04-06
    1,4-Dihydropyridines bearing carbonyl functions in the 3- and 5-positions, being optionally substituted by lower alkyl in the 6-position, being substituted in the 4-position by lower alkyl, phenyl, substituted phenyl or a heterocyclic group, and being fused through the 1- and 2-positions to a five, six or seven membered cycloalkyl ring, one methylene group of which can be replaced by sulfur, oxygen imino or alkylimino, are anti-hypertensive agents and coronary vessel dilators. The compounds, of which 6-methyl-4-(3-nitrophenyl)-1,2-pentamethylene-1,4-dihydropridine-3,5-dicar boxylic acid 3,5-diethyl ester is a representative embodiment, are prepared through condensation of an ylideneacetoacetic acid ester and a cyclic enamino carbonyl derivative.
    3-和5-位带有羰基功能的1,4-二氢吡啶,6-位可选择性地被低烷基取代,4-位被低烷基、苯基、取代苯基或杂环基取代,通过1-和2-位与五、六或七元环环烷基融合,其中一个亚甲基可以被、氧、亚胺或烷基亚胺取代,是降压剂和冠状血管扩张剂。这些化合物通过酰乙酸乙酯和环状烯酮羰基衍生物的缩合反应制备而成,其中6-甲基-4-(3-硝基苯基)-1,2-戊亚甲基-1,4-二氢吡啶-3,5-二羧酸乙酯是一种代表性的实施例。
  • Tetrahydroindolizine derivatives
    申请人:Bayer Aktiengesellschaft
    公开号:US03951994A1
    公开(公告)日:1976-04-20
    1,4-Dihydropyridines bearing carbonyl functions in the 3- and 5-positions, being optionally substituted by lower alkyl in the 6-position, being substituted in the 4-position by lower alkyl, phenyl, substituted phenyl or a heterocyclic group, and being fused through the 1- and 2-positions to a five, six or seven membered cycloalkyl ring, one methylene group of which can be replaced by sulfur, oxygen imino or alkylimino, are antihypertensive agents and coronary vessel dilators. The compounds, of which 6-methyl-4-(3-nitrophenyl)-1,2-pentamethylene-1,4-dihydropyridine-3,5-dica rboxylic acid 3,5-diethyl ester is a representative embodiment, are prepared through condensation of an ylideneacetoacetic acid ester and a cyclic enamino carbonyl derivative.
    3-和5-位带有羰基功能的1,4-二氢吡啶,可在6-位被低烷基取代,4-位被低烷基、苯基、取代苯基或杂环基取代,并通过1-和2-位融合到五、六或七元环环烷基环上,其中一个亚甲基可以被、氧、亚基或烷基亚基替换,是降压剂和冠状血管扩张剂。这些化合物的代表性实施例是6-甲基-4-(3-硝基苯基)-1,2-戊亚甲基-1,4-二氢吡啶-3,5-二羧酸3,5-二乙酯,通过酰乙酰乙酸酯和环状烯酰亚胺羰基衍生物的缩合制备。
  • Bicyclic derivatives of 1,4-dihydropyridine as antihypertensive agents
    申请人:Bayer Aktiengesellschaft
    公开号:US04004015A1
    公开(公告)日:1977-01-18
    1,4-Dihydropyridines bearing carbonyl functions in the 3- and 5-positions, being optionally substituted by lower alkyl in the 6-position, being substituted in the 4-position by lower alkyl, phenyl, substituted phenyl or a heterocyclic group, and being fused through the 1- and 2-positions to a five, six or seven membered cycloalkyl ring, one methylene group of which can be replaced by sulfur, oxygen imino or alkylimino, are antihypertensive agents and coronary vessel dilators. The compounds, of which 6-methyl-4-(3-nitrophenyl)-1,2-pentamethylene-1,4-dihydropyridine-3,5-dica rboxylic acid 3,5-diethyl ester is a representative embodiment, are prepared through condensation of an ylideneacetoacetic acid ester and a cyclic enamino carbonyl derivative.
    3-和5-位带有羰基功能的1,4-二氢吡啶,可在6-位被低碳基取代,在4-位被低碳基、苯基、取代苯基或杂环基取代,并通过1-和2-位融合到五、六或七元环烷基环上,其中一个亚甲基可以被、氧、亚基或烷基亚基取代,是抗高血压药物和冠状血管扩张剂。这些化合物通过酰乙酰乙酸酯和环状烯酮羰基衍生物的缩合制备,其中6-甲基-4-(3-硝基苯基)-1,2-戊亚甲基-1,4-二氢吡啶-3,5-二羧酸乙酯是一个典型的实施例。
查看更多

同类化合物

()-2-(5-甲基-2-氧代苯并呋喃-3(2)-亚乙基)乙酸乙酯 (双(2,2,2-三氯乙基)) (乙基N-(1H-吲唑-3-基羰基)ethanehydrazonoate) (Z)-3-[[[2,4-二甲基-3-(乙氧羰基)吡咯-5-基]亚甲基]吲哚-2--2- (S)-(-)-5'-苄氧基苯基卡维地洛 (S)-(-)-2-(α-(叔丁基)甲胺)-1H-苯并咪唑 (S)-(-)-2-(α-甲基甲胺)-1H-苯并咪唑 (S)-氨氯地平-d4 (S)-8-氟苯并二氢吡喃-4-胺 (S)-4-(叔丁基)-2-(喹啉-2-基)-4,5-二氢噁唑 (S)-4-氯-1,2-环氧丁烷 (S)-3-(2-(二氟甲基)吡啶-4-基)-7-氟-3-(3-(嘧啶-5-基)苯基)-3H-异吲哚-1-胺 (S)-2-(环丁基氨基)-N-(3-(3,4-二氢异喹啉-2(1H)-基)-2-羟丙基)异烟酰胺 (SP-4-1)-二氯双(喹啉)-钯 (SP-4-1)-二氯双(1-苯基-1H-咪唑-κN3)-钯 (R,S)-可替宁N-氧化物-甲基-d3 (R,S)-六氢-3H-1,2,3-苯并噻唑-2,2-二氧化物-3-羧酸叔丁酯 (R)-(+)-5'-苄氧基卡维地洛 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-卡洛芬 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (R)-4-异丙基-2-恶唑烷硫酮 (R)-3-甲基哌啶盐酸盐; (R)-2-苄基哌啶-1-羧酸叔丁酯 (N-(Boc)-2-吲哚基)二甲基硅烷醇钠 (N-{4-[(6-溴-2-氧代-1,3-苯并恶唑-3(2H)-基)磺酰基]苯基}乙酰胺) (E)-2-氰基-3-(5-(2-辛基-7-(4-(对甲苯基)-1,2,3,3a,4,8b-六氢环戊[b]吲哚-7-基)-2H-苯并[d][1,2,3]三唑-4-基)噻吩-2-基)丙烯酸 (E)-2-氰基-3-[5-(2,5-二氯苯基)呋喃-2-基]-N-喹啉-8-基丙-2-烯酰胺 (8α,9S)-(+)-9-氨基-七氢呋喃-6''-醇,值90% (6R,7R)-7-苯基乙酰胺基-3-[(Z)-2-(4-甲基噻唑-5-基)乙烯基]-3-头孢唑啉-4-羧酸二苯甲基酯 (6-羟基嘧啶-4-基)乙酸 (6,7-二甲氧基-4-(3,4,5-三甲氧基苯基)喹啉) (6,6-二甲基-3-(甲硫基)-1,6-二氢-1,2,4-三嗪-5(2H)-硫酮) (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5R,Z)-3-(羟基((1R,2S,6S,8aS)-1,3,6-三甲基-2-((E)-prop-1-en-1-yl)-1,2,4a,5,6,7,8,8a-八氢萘-1-基)亚甲基)-5-(羟甲基)-1-甲基吡咯烷-2,4-二酮 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-(4-乙氧基-3-甲基苄基)-1,3-苯并二恶茂) (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氯-2,1,3-苯并噻二唑-4-基)-氨基甲氨基硫代甲酸甲酯一氢碘 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (5-氨基-1,3,4-噻二唑-2-基)甲醇 (4aS-反式)-八氢-1H-吡咯并[3,4-b]吡啶 (4aS,9bR)-6-溴-2,3,4,4a,5,9b-六氢-1H-吡啶并[4,3-B]吲哚 (4S,4''S)-2,2''-环亚丙基双[4-叔丁基-4,5-二氢恶唑] (4-(4-氯苯基)硫代)-10-甲基-7H-benzimidazo(2,1-A)奔驰(德)isoquinolin-7一 (4-苄基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4-甲基环戊-1-烯-1-基)(吗啉-4-基)甲酮 (4-己基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4,5-二甲氧基-1,2,3,6-四氢哒嗪)